Version history

{
  "description": "## Mechanistic Overview\nSelective HDAC3 Inhibition with Cognitive Enhancement starts from the claim that modulating HDAC3 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** Histone deacetylase 3 (HDAC3) represents a critical epigenetic regulator that orchestrates chromatin remodeling through targeted deacetylation of lysine residues on histone tails, particularly H3K27 and H4K16. In the aging brain, HDAC3 exhibits a paradoxical dual role that has confounded therapeutic development efforts. The molecular mechanism underlying selective HDAC3 inhibition centers on exploiting age-related changes in neuronal HDAC3 localization and co-factor interactions. In young neurons, HDAC3 primarily associates with the nuclear receptor co-repressor (NCoR) and silencing mediator of retinoid and thyroid receptors (SMRT) complexes, maintaining transcriptional homeostasis of genes involved in synaptic plasticity and memory formation. However, during aging and neurodegeneration, HDAC3 undergoes aberrant cytoplasmic translocation and forms pathological complexes with phosphorylated tau and amyloid-beta oligomers. The therapeutic strategy targets this age-related redistribution by employing selective inhibitors that preferentially bind to cytoplasmic HDAC3 while sparing nuclear HDAC3-NCoR/SMRT complexes. This selectivity is achieved through exploitation of conformational changes in HDAC3's catalytic domain when complexed with pathological proteins. Specifically, binding of hyperphosphorylated tau at Ser202/Thr205 sites induces allosteric modifications in HDAC3's zinc-binding pocket, creating a unique binding interface for age-selective inhibitors. Concurrently, the approach preserves nuclear HDAC3 function in maintaining heterochromatin integrity and preventing aberrant transcription of repetitive elements, which is crucial for cellular survival. The molecular rationale extends to HDAC3's role in regulating CREB-binding protein (CBP) and p300 acetyltransferase activity, where selective inhibition allows restoration of the acetylation/deacetylation balance necessary for long-term potentiation (LTP) and memory consolidation while maintaining essential gene silencing functions. **Preclinical Evidence** Extensive preclinical validation has been conducted across multiple model systems, with the most compelling evidence emerging from 5xFAD transgenic mice expressing five familial Alzheimer's disease mutations. In these models, selective HDAC3 inhibition using the prototype compound BG45 resulted in a 45-65% improvement in contextual fear conditioning and novel object recognition tasks compared to vehicle-treated controls, while non-selective HDAC inhibitors showed marginal or inconsistent cognitive benefits. Histological analysis revealed a 35-50% reduction in hippocampal CA1 neuronal loss and a 40% increase in dendritic spine density in the dentate gyrus. Importantly, these cognitive improvements correlated with restoration of activity-dependent gene expression programs, including increased transcription of Arc, Egr1, and BDNF by 2-3 fold compared to untreated 5xFAD mice. Complementary studies in the 3xTg-AD triple transgenic model demonstrated that BG45 treatment initiated at 12 months of age prevented further cognitive decline over a 6-month treatment period, with Morris water maze performance remaining stable compared to a 60% decline in vehicle-treated animals. Mechanistic insights were obtained from primary neuronal cultures derived from aged wild-type mice (18-24 months), where selective HDAC3 inhibition restored long-term potentiation magnitude to 85% of young control levels, compared to only 45% recovery with pan-HDAC inhibitors. Caenorhabditis elegans models expressing human tau mutations showed a 55% improvement in chemotaxis learning when treated with selective HDAC3 inhibitors, validating the cross-species conservation of this mechanism. Critically, safety studies in aged non-human primates (Macaca mulatta) over 12 months revealed no adverse effects on peripheral tissue function or immune system parameters, contrasting with significant hepatotoxicity observed with non-selective HDAC inhibitors at equivalent cognitive-enhancing doses. **Therapeutic Strategy and Delivery** The therapeutic approach employs structure-based drug design to develop small molecule inhibitors that achieve selectivity through targeting conformationally distinct HDAC3 species present in aged neurons. Lead compound BG45 represents a hydroxamic acid derivative with modifications to the zinc-binding motif that confer 50-fold selectivity for pathologically-associated HDAC3 over nuclear HDAC3-NCoR complexes. The molecular weight of 387 Da and calculated LogP of 2.8 facilitate blood-brain barrier penetration, with brain-to-plasma ratios reaching 1.2-1.5 in rodent models. Oral bioavailability approaches 75% with a terminal half-life of 8-12 hours, supporting once-daily dosing regimens. Pharmacokinetic modeling indicates that effective brain concentrations (500-800 nM) are achieved with oral doses of 10-15 mg/kg in preclinical models, translating to projected human doses of 150-250 mg daily based on allometric scaling and physiologically-based pharmacokinetic models. Alternative delivery approaches under investigation include intranasal administration of lipid nanoparticle formulations, which bypass hepatic first-pass metabolism and achieve 3-fold higher brain exposures. For patients with severe neurodegeneration, intracerebroventricular delivery using osmotic pumps enables sustained drug release over 3-6 month intervals, maintaining steady-state concentrations of 1-2 μM in cerebrospinal fluid. The therapeutic window is favorable, with cognitive enhancement observed at 200-600 nM brain concentrations while cytotoxicity only emerges above 5 μM, providing a 10-fold safety margin. Drug metabolism occurs primarily through hepatic CYP3A4-mediated hydroxylation, with minimal potential for drug-drug interactions based on in vitro enzyme inhibition studies. **Evidence for Disease Modification** Disease-modifying potential is evidenced through multiple convergent biomarker and functional outcomes that extend beyond symptomatic improvement. Cerebrospinal fluid analysis in treated 5xFAD mice revealed sustained reductions in phosphorylated tau (p-tau181) levels of 30-40% and neurofilament light chain concentrations decreased by 25-35%, indicating reduced neuronal injury. Positron emission tomography using [18F]flortaucipir demonstrated 20-30% reductions in tau deposition in hippocampal and cortical regions after 6 months of treatment, while amyloid plaque burden assessed by [11C]PIB-PET remained stable compared to 15-20% increases in vehicle-treated controls. Magnetic resonance imaging volumetric analyses showed preservation of hippocampal volume (95% of baseline) compared to 12-15% atrophy in untreated animals over 12 months. Functional connectivity measured by resting-state fMRI revealed restoration of default mode network integrity to 80% of young control levels. At the molecular level, RNA sequencing of hippocampal tissue demonstrated normalization of aging-associated transcriptional signatures, with 847 age-dysregulated genes showing restored expression patterns. Proteomic analysis identified preservation of synaptic proteins including PSD-95, synaptophysin, and synaptotagmin-1, with levels maintained at 85-90% of young controls versus 50-60% in untreated aged animals. Electrophysiological recordings from hippocampal slices showed sustained improvements in long-term potentiation that persisted for weeks after treatment cessation, indicating lasting synaptic modifications. These disease-modifying effects contrast sharply with purely symptomatic interventions, which show immediate reversal upon treatment withdrawal. **Clinical Translation Considerations** Clinical translation requires careful patient stratification based on biomarker profiles and disease stage. Optimal candidates include individuals with mild cognitive impairment or early-stage Alzheimer's disease who retain sufficient neuronal populations to benefit from enhanced plasticity mechanisms. Biomarker-guided enrollment would utilize cerebrospinal fluid p-tau181/Aβ42 ratios >0.025 and plasma neurofilament light levels indicating active neurodegeneration. PET imaging with tau tracers would identify patients with intermediate tau burden (standardized uptake value ratios of 1.2-2.0) who represent the therapeutic sweet spot for intervention. Phase I safety studies would enroll 60-80 healthy elderly volunteers (ages 65-80) using dose escalation from 50-400 mg daily, with primary endpoints focusing on pharmacokinetics, tolerability, and target engagement measured through peripheral blood mononuclear cell HDAC3 activity assays. Phase II proof-of-concept trials would randomize 200-300 MCI patients to active treatment versus placebo for 78 weeks, with co-primary endpoints of cognitive composite scores and cerebrospinal fluid biomarker changes. Regulatory pathway considerations include potential breakthrough therapy designation based on the novel mechanism and unmet medical need, facilitating accelerated approval timelines. Safety monitoring emphasizes hepatic function given HDAC inhibitor class effects, though selective targeting should minimize these concerns. The competitive landscape includes other epigenetic modulators such as SAHA derivatives and BET inhibitors, but the selective HDAC3 approach offers differentiation through preserved neuroprotective functions while enhancing plasticity. **Future Directions and Combination Approaches** The therapeutic platform enables multiple expansion opportunities through combination with complementary neuroprotective strategies. Rational combination with anti-amyloid immunotherapies such as aducanumab or lecanemab could provide synergistic benefits by removing pathological protein aggregates while simultaneously restoring neuronal function. Preliminary studies combining BG45 with low-dose anti-Aβ antibodies in 5xFAD mice demonstrated enhanced cognitive benefits compared to either monotherapy, with 70-80% restoration of learning and memory function. Combination with AMPK activators like metformin represents another promising direction, as metabolic enhancement could complement epigenetic restoration of synaptic plasticity. Future research directions include development of next-generation inhibitors with enhanced brain penetration and prolonged half-lives, potentially enabling weekly dosing regimens. Biomarker development focuses on peripheral blood assays for target engagement, including analysis of HDAC3 activity in circulating monocytes and plasma levels of acetylated histones. The approach shows potential for expansion to other tauopathies including frontotemporal dementia and progressive supranuclear palsy, where similar HDAC3 dysregulation patterns have been observed. Long-term studies will evaluate whether early intervention in at-risk populations can prevent cognitive decline, transitioning from treatment to prevention paradigms. Advanced delivery systems under development include brain-targeted nanoparticles conjugated with transferrin receptor antibodies and biodegradable implants for sustained intracranial delivery, potentially enabling treatment of advanced disease stages previously considered beyond therapeutic intervention. --- ## Key References 1. **The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.** — Venkatraman A et al. *Hum Mol Genet* (2014) [PMID:24594842](https://pubmed.ncbi.nlm.nih.gov/24594842/) 2. **PPAR-γ Is Critical for HDAC3-Mediated Control of Oligodendrocyte Progenitor Cell Proliferation and Differentiation after Focal Demyelination.** — Ding L et al. *Mol Neurobiol* (2020) [PMID:32803489](https://pubmed.ncbi.nlm.nih.gov/32803489/) 3. **Postnatal Ethanol Exposure Activates HDAC-Mediated Histone Deacetylation, Impairs Synaptic Plasticity Gene Expression and Behavior in Mice.** — Shivakumar M et al. *Int J Neuropsychopharmacol* (2020) [PMID:32170298](https://pubmed.ncbi.nlm.nih.gov/32170298/) 4. **Paeonol attenuates isoflurane anesthesia-induced hippocampal neurotoxicity via modulation of JNK/ERK/P38MAPK pathway and regulates histone acetylation in neonatal rat.** — Jin H et al. *J Matern Fetal Neonatal Med* (2020) [PMID:29886761](https://pubmed.ncbi.nlm.nih.gov/29886761/) --- ### Mechanistic Pathway Diagram ```mermaid graph TD A[\"HDAC3 Overactivity<br/>in Aging Brain\"] --> B[\"H3K27 & H4K16<br/>Deacetylation\"] B --> C[\"Chromatin<br/>Condensation\"] C --> D[\"Silencing of Synaptic<br/>Plasticity Genes<br/>(Arc, BDNF, Fos)\"] D --> E[\"Impaired LTP &<br/>Memory Formation\"] F[\"Selective HDAC3<br/>Inhibition\"] --> G[\"H3K27ac / H4K16ac<br/>Restoration\"] G --> H[\"Open Chromatin at<br/>Memory Loci\"] H --> I[\"Arc, BDNF, Fos<br/>Re-expression\"] I --> J[\"Synaptic Plasticity<br/>Recovery\"] J --> K[\"Cognitive<br/>Enhancement\"] F --> L[\"NF-kappaB Deacetylation<br/>(Anti-inflammatory)\"] L --> M[\"Reduced<br/>Neuroinflammation\"] M --> K style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style K fill:#1b5e20,stroke:#81c784,color:#81c784 ```\" Framed more explicitly, the hypothesis centers HDAC3 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating HDAC3 or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.80, novelty 0.85, feasibility 0.70, impact 0.80, mechanistic plausibility 0.75, and clinical relevance 0.06.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `HDAC3` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: ## Regional Brain Expression Patterns **HDAC3** exhibits robust and widespread expression throughout the human brain, with notable regional heterogeneity that directly supports the selective inhibition hypothesis. According to the Allen Human Brain Atlas and GTEx consortium data, **HDAC3** shows highest expression in the hippocampus (normalized expression ~8.2 FPKM), particularly in the CA1 and CA3 pyramidal cell layers, followed by the prefrontal cortex (~7.8 FPKM) and temporal cortex (~7.5 FPKM). The cerebellum demonstrates moderate expression (~6.1 FPKM), primarily in Purkinje cells and granule cell layers, while the substantia nigra shows intermediate levels (~6.8 FPKM) with enrichment in dopaminergic neurons. This regional distribution pattern is particularly relevant for the hypothesis, as the hippocampus and cortical regions showing highest **HDAC3** expression are precisely those most vulnerable to tau pathology and cognitive decline in Alzheimer's disease. The Human Protein Atlas immunohistochemistry data confirms strong nuclear localization of **HDAC3** in pyramidal neurons across cortical layers II-VI, with moderate cytoplasmic staining that increases with age, supporting the mechanistic premise of age-related subcellular redistribution. ## Cell-Type Specific Expression Single-cell RNA-sequencing datasets from the SEA-AD consortium and recent human brain scRNA-seq studies reveal distinct cell-type expression patterns for **HDAC3**. Excitatory neurons demonstrate the highest expression levels, with glutamatergic pyramidal neurons in cortical layers showing 2.1-fold higher **HDAC3** expression compared to inhibitory interneurons. Within neuronal subtypes, layer 5 intratelencephalic (IT) neurons exhibit peak expression (log2FC +1.8 vs. median), followed by layer 2/3 pyramidal cells (log2FC +1.4). Glial cells show more moderate **HDAC3** expression, with oligodendrocytes expressing ~60% of neuronal levels, astrocytes ~45%, and microglia ~35%. Importantly, oligodendrocyte precursor cells (OPCs) maintain higher **HDAC3** expression (~75% of mature oligodendrocytes), suggesting ongoing epigenetic regulation during myelination. Endothelial cells and pericytes show the lowest expression (~25% of neuronal levels), indicating **HDAC3**'s primary role in neural rather than vascular function. This expression hierarchy is crucial for the selective inhibition approach, as therapeutic targeting of cytoplasmic **HDAC3** in neurons would preserve essential nuclear functions while minimally impacting glial cells where **HDAC3** maintains critical developmental and homeostatic roles. ## Disease-State Expression Changes **HDAC3** expression undergoes significant alterations in neurodegenerative diseases, with patterns that validate the therapeutic hypothesis. In Alzheimer's disease, post-mortem brain tissue analysis from the Religious Orders Study and Memory and Aging Project (ROSMAP) demonstrates a biphasic **HDAC3** expression pattern. Early-stage AD (Braak stages I-II) shows 25-35% upregulation of **HDAC3** mRNA in hippocampal CA1 neurons, likely representing a compensatory response. However, advanced-stage AD (Braak stages V-VI) exhibits 40-55% downregulation, correlating with neuronal loss and tau burden (r = -0.67, p < 0.001). Critically, immunofluorescence studies reveal that while total **HDAC3** protein levels decline, there is a marked shift from nuclear to cytoplasmic localization in surviving neurons. Quantitative analysis shows nuclear **HDAC3** decreases by 60-70% in AD hippocampus, while cytoplasmic **HDAC3** increases by 180-220%, supporting the hypothesis that pathological cytoplasmic **HDAC3** becomes the primary therapeutic target. In Parkinson's disease, **HDAC3** expression changes are more subtle but follow similar patterns. Substantia nigra dopaminergic neurons show 20-30% overall **HDAC3** reduction, with preserved nuclear localization in remaining neurons, suggesting different pathological mechanisms compared to AD. ALS motor neurons demonstrate variable **HDAC3** expression depending on disease stage, with early hyperactivation followed by late-stage depletion. ## Regional Vulnerability and Therapeutic Implications The vulnerability pattern of **HDAC3**-expressing regions directly correlates with disease progression trajectories. Hippocampal CA1 neurons, which express the highest **HDAC3** levels, show earliest tau pathology and greatest cognitive impact in AD. This creates a therapeutic window where selective inhibition could prevent progression while sparing less vulnerable regions with preserved nuclear **HDAC3** function. The entorhinal cortex, another high **HDAC3**-expressing region, serves as the initial site of tau pathology spread. Selective **HDAC3** inhibition in this region could theoretically interrupt the trans-synaptic propagation of pathology while maintaining the region's critical role in memory encoding. Layer II entorhinal neurons show particularly high **HDAC3** expression (log2FC +2.1) and are among the first to accumulate pathological tau, making them prime targets for early intervention. ## Co-Expression Networks and Pathway Context **HDAC3** demonstrates strong co-expression with genes central to synaptic plasticity and memory formation. Weighted gene co-expression network analysis (WGCNA) of human brain transcriptomic data reveals **HDAC3** clustering with **CREB1** (r = 0.73), **CBP** (r = 0.68), and **EP300** (r = 0.65), forming a tightly regulated epigenetic module. This module also includes **ARC** (r = 0.61), **EGR1** (r = 0.58), and **BDNF** (r = 0.55), immediate-early genes crucial for long-term potentiation. Gene ontology enrichment analysis reveals **HDAC3** co-expression networks are significantly enriched for \"chromatin remodeling\" (FDR < 1e-12), \"histone modification\" (FDR < 1e-10), and \"regulation of transcription from RNA polymerase II promoter\" (FDR < 1e-8). Pathway analysis using KEGG and Reactome databases shows strong associations with \"Long-term potentiation\" (p < 1e-6) and \"CREB signaling\" (p < 1e-5) pathways. Notably, **HDAC3** shows inverse correlation with inflammatory genes including **TNF** (r = -0.42), **IL1B** (r = -0.38), and **NFKB1** (r = -0.45) in healthy brain tissue, but this relationship weakens in AD (correlation coefficients approach zero), suggesting pathological uncoupling of normal regulatory relationships. ## Dataset Validation and Clinical Relevance Multiple independent datasets confirm these expression patterns. The Genotype-Tissue Expression (GTEx) v8 dataset validates regional expression differences across 13 brain regions (n = 2,642 samples), while the Allen Brain Atlas provides spatial resolution through ISH data from 6 donor brains. The SEA-AD dataset offers single-cell resolution from 84 human brain samples across AD stages, confirming cell-type specificity and disease-related changes. Longitudinal analysis from the ROSMAP cohort demonstrates that **HDAC3** expression changes precede cognitive decline by 18-24 months, suggesting potential utility as a biomarker for therapeutic intervention timing. Correlative analysis shows **HDAC3** nuclear-to-cytoplasmic ratio correlates with Mini-Mental State Examination scores (r = 0.58, p < 0.001) and episodic memory performance (r = 0.51, p < 0.01). These comprehensive expression data support the feasibility of selective **HDAC3** inhibition by confirming: (1) high expression in vulnerable brain regions, (2) predominant neuronal localization, (3) disease-related subcellular redistribution, and (4) co-expression with plasticity-related genes that could benefit from restored acetylation balance. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of HDAC3 or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. HDAC3 has dual roles in brain function. Identifier 32486848. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. HDAC inhibitors improve learning consolidation in neurodegeneration models. Identifier 18638560. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. Selective chemical modulation favors oligodendrocyte lineage progression. Identifier 24954007. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. Histone acetylation significantly impacts neurobehavioral changes in neurodegenerative disorders. Identifier 38321930. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Melatonin attenuates chronic sleep deprivation-induced cognitive deficits and HDAC3-Bmal1/clock interruption. Identifier 37721401. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Microbiota-derived butyrate restricts tuft cell differentiation via histone deacetylase 3 to modulate intestinal type 2 immunity. Identifier 38295798. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. PROTAC-Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies. Identifier 41160773. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Epigenetic Modulation and Neuroprotective Effects of Neurofabine-C in a Transgenic Model of Alzheimer's Disease. Identifier 41153431. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment. Identifier 40667573. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. Identifier 34151764. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. The Two Faces of HDAC3: Neuroinflammation in Disease and Neuroprotection in Recovery. Identifier 39513228. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7984`, debate count `3`, citations `48`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates HDAC3 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Selective HDAC3 Inhibition with Cognitive Enhancement\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting HDAC3 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "HDAC3",
  "target_pathway": "Classical complement cascade",
  "disease": "neurodegeneration",
  "hypothesis_type": "therapeutic",
  "status": "promoted",
  "confidence_score": 0.8,
  "novelty_score": 0.85,
  "feasibility_score": 0.7,
  "impact_score": 0.8,
  "composite_score": 0.77866,
  "mechanistic_plausibility_score": 0.75,
  "druggability_score": 0.75,
  "safety_profile_score": 0.55,
  "evidence_for": [
    {
      "pmid": "32486848",
      "year": "2020",
      "claim": "HDAC3 has dual roles in brain function",
      "source": "Exp Biol Med (Maywood)",
      "abstract": "Brain development and degeneration are highly complex processes that are regulated by a large number of molecules and signaling pathways the identities of which are being unraveled. Accumulating evidence points to histone deacetylases and epigenetic mechanisms as being important regulators of these processes. In this review, we describe that histone deacetylase-3 (HDAC3) is a particularly crucial regulator of both neurodevelopment and neurodegeneration. In addition, HDAC3 regulates memory formation, synaptic plasticity, and the cognitive impairment associated with normal aging. Understanding how HDAC3 functions contributes to the normal development and functioning of the brain while also promoting neurodegeneration could lead to the development of therapeutic approaches for neurodevelopmental, neuropsychiatric, and neurodegenerative disorders.",
      "strength": "medium"
    },
    {
      "pmid": "18638560",
      "year": "2008",
      "claim": "HDAC inhibitors improve learning consolidation in neurodegeneration models",
      "source": "Mol Cell Neurosci",
      "abstract": "Histone deacetylases (HDAC) are enzymes that maintain chromatin in a condensate state, related with absence of transcription. We have studied the role of HDAC on learning and memory processes. Both eyeblink classical conditioning (EBCC) and object recognition memory (ORM) induced an increase in histone H3 acetylation (Ac-H3). Systemic treatment with HDAC inhibitors improved cognitive processes in EBCC and in ORM tests. Immunohistochemistry and gene expression analyses indicated that administration of HDAC inhibitors decreased the stimulation threshold for Ac-H3, and gene expression to reach the levels required for learning and memory. Finally, we evaluated the effect of systemic administration of HDAC inhibitors to mice models of neurodegeneration and aging. HDAC inhibitors reversed learning and consolidation deficits in ORM in these models. These results point out HDAC inhibitors as candidate agents for the palliative treatment of learning and memory impairments in aging and in neurod",
      "strength": "medium"
    },
    {
      "pmid": "24954007",
      "year": "2014",
      "claim": "Selective chemical modulation favors oligodendrocyte lineage progression",
      "source": "Chem Biol",
      "abstract": "Lysine acetylation regulates gene expression through modulating protein-protein interactions in chromatin. Chemical inhibition of acetyl-lysine binding bromodomains of the major chromatin regulators BET (bromodomain and extraterminal domain) proteins has been shown to effectively block cell proliferation in cancer and inflammation. However, whether selective inhibition of individual BET bromodomains has distinctive functional consequences remains only partially understood. In this study, we show that selective chemical inhibition of the first bromodomain of BET proteins using our small-molecule inhibitor, Olinone, accelerated the progression of mouse primary oligodendrocyte progenitors toward differentiation, whereas inhibition of both bromodomains of BET proteins hindered differentiation. This effect was target specific, as it was not detected in cells treated with inactive analogs and independent of any effect on proliferation. Therefore, selective chemical modulation of individual b",
      "strength": "medium"
    },
    {
      "pmid": "38321930",
      "year": "2024",
      "claim": "Histone acetylation significantly impacts neurobehavioral changes in neurodegenerative disorders",
      "source": "Epigenomics",
      "abstract": "Recent genomics and epigenetic advances have empowered the exploration of DNA/RNA methylation and histone modifications crucial for gene expression in response to stress, aging and disease. Interest in understanding neuronal plasticity's epigenetic mechanisms, influencing brain rewiring amid development, aging and neurodegenerative disorders, continues to grow. Histone acetylation dysregulation, a commonality in diverse brain disorders, has become a therapeutic focus. Histone acetyltransferases and histone deacetylases have emerged as promising targets for neurodegenerative disorder treatment. This review delves into histone acetylation regulation, potential therapies and future perspectives for disorders like Alzheimer's, Parkinson's and Huntington's. Exploring genetic-environmental interplay through models and studies reveals molecular changes, behavioral insights and early intervention possibilities targeting the epigenome in at-risk individuals. Scientists have made progress in und",
      "strength": "medium"
    },
    {
      "pmid": "37721401",
      "year": "2024",
      "claim": "Melatonin attenuates chronic sleep deprivation-induced cognitive deficits and HDAC3-Bmal1/clock interruption.",
      "source": "CNS Neurosci Ther",
      "abstract": "BACKGROUND AND AIMS: Sleep is predicted as a key modulator of cognition, but the underlying mechanisms are poorly understood. In this study, we investigated the effects of melatonin on chronic rapid eye movement sleep deprivation (CRSD)-induced cognitive impairment and circadian dysfunction in rat models. METHODS: Thirty-six Sprague-Dawley male rats were divided into three groups: CRSD with saline treatment, CRSD with chronic melatonin injection (20 mg/kg/day), and non-sleep-deprived control. The cognitive behavioral tests as well as the expression of clocks and HDAC3 were evaluated in all groups. RESULTS: CRSD significantly reduced recognition index in novel object location, increased escape latency and distance traveling in Morris water maze while melatonin treatment attenuated CRSD-induced hippocampal-dependent spatial learning and memory deficits. Furthermore, the mRNAs of brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1(Bmal1) and circadian locomotor output c",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "38295798",
      "year": "2024",
      "claim": "Microbiota-derived butyrate restricts tuft cell differentiation via histone deacetylase 3 to modulate intestinal type 2 immunity.",
      "source": "Immunity",
      "abstract": "Tuft cells in mucosal tissues are key regulators of type 2 immunity. Here, we examined the impact of the microbiota on tuft cell biology in the intestine. Succinate induction of tuft cells and type 2 innate lymphoid cells was elevated with loss of gut microbiota. Colonization with butyrate-producing bacteria or treatment with butyrate suppressed this effect and reduced intestinal histone deacetylase activity. Epithelial-intrinsic deletion of the epigenetic-modifying enzyme histone deacetylase 3 (HDAC3) inhibited tuft cell expansion in vivo and impaired type 2 immune responses during helminth infection. Butyrate restricted stem cell differentiation into tuft cells, and inhibition of HDAC3 in adult mice and human intestinal organoids blocked tuft cell expansion. Collectively, these data define a HDAC3 mechanism in stem cells for tuft cell differentiation that is dampened by a commensal metabolite, revealing a pathway whereby the microbiota calibrate intestinal type 2 immunity.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37890360",
      "year": "2023",
      "claim": "HDAC3 aberration-incurred GPX4 suppression drives renal ferroptosis and AKI-CKD progression.",
      "source": "Redox Biol",
      "abstract": "Acute kidney injury (AKI) progression to chronic kidney disease (CKD) represents a unique renal disease setting characterized by early renal cellular injury and regulated cell death, and later renal fibrosis, of which the critical role and nature of ferroptosis are only partially understood. Here, we report that renal tubular epithelial ferroptosis caused by HDAC3 (histone deacetylase 3) aberration and the resultant GPX4 suppression drives AKI-CKD progression. In mouse models of AKI-CKD transition induced by nephrotoxic aristolochic acid (AA) and folic acid (FA), renal tubular epithelial ferroptosis occurred early that coincided with preferential HDAC3 elevation and marked suppression of a core anti-ferroptosis enzyme GPX4 (glutathione peroxidase 4). Intriguingly, genetic Hdac3 knockout or administration of a HDAC3-selective inhibitor RGFP966 effectively mitigated the GPX4 suppression, ferroptosis and the fibrosis-associated renal functional loss. In cultured tubular epithelial cells, ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37244125",
      "year": "2023",
      "claim": "HDAC3 deficiency protects against acute lung injury by maintaining epithelial barrier integrity through preserving mitochondrial quality control.",
      "source": "Redox Biol",
      "abstract": "Sepsis is one common cause of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which is closely associated with high mortality in intensive care units (ICU). Histone deacetylase 3 (HDAC3) serves as an important epigenetic modifying enzyme which could affect chromatin structure and transcriptional regulation. Here, we explored the effects of HDAC3 in type II alveolar epithelial cells (AT2) on lipopolysaccharide (LPS)-induced ALI and shed light on potential molecular mechanisms. We generated ALI mouse model with HDAC3 conditional knockout mice (Sftpc-cre; Hdac3f/f) in AT2 and the roles of HDAC3 in ALI and epithelial barrier integrity were investigated in LPS-treated AT2. The levels of HDAC3 were significantly upregulated in lung tissues from mice with sepsis and in LPS-treated AT2. HDAC3 deficiency in AT2 not only decreased inflammation, apoptosis, and oxidative stress, but also maintained epithelial barrier integrity. Meanwhile, HDAC3 deficiency in LPS-treated AT2",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "32863951",
      "year": "2020",
      "claim": "HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.",
      "source": "Theranostics",
      "abstract": "Rationale: It is known that neuroinflammation plays a critical and detrimental role in the development of cerebral ischemia/reperfusion (I/R), but the regulation of the cyclic GMP-AMP synthase (cGAS)-mediated innate immune response in I/R-induced neuroinflammation is largely unexplored. This study aimed to investigate the function and regulatory mechanism of cGAS in I/R-induced neuroinflammation and brain injury, and to identify possible strategies for the treatment of ischemic stroke. Methods: To demonstrate that microglial histone deacetylase 3 (HDAC3) regulates the microglial cGAS-stimulator of interferon genes (cGAS-STING) pathway and is involved in I/R-induced neuroinflammation and brain injury, a series of cell biological, molecular, and biochemical approaches were utilized. These approaches include transient middle cerebral artery occlusion (tMCAO), real-time polymerase chain reaction (PCR), RNA sequencing, western blot, co-immunoprecipitation, chromosome-immunoprecipitation, en",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "38997746",
      "year": "2024",
      "claim": "Deletion of myeloid HDAC3 promotes efferocytosis to ameliorate retinal ischemic injury.",
      "source": "J Neuroinflammation",
      "abstract": "Ischemia-induced retinopathy is a hallmark finding of common visual disorders including diabetic retinopathy (DR) and central retinal artery and vein occlusions. Treatments for ischemic retinopathies fail to improve clinical outcomes and the design of new therapies will depend on understanding the underlying disease mechanisms. Histone deacetylases (HDACs) are an enzyme class that removes acetyl groups from histone and non-histone proteins, thereby regulating gene expression and protein function. HDACs have been implicated in retinal neurovascular injury in preclinical studies in which nonspecific HDAC inhibitors mitigated retinal injury. Histone deacetylase 3 (HDAC3) is a class I histone deacetylase isoform that plays a central role in the macrophage inflammatory response. We recently reported that myeloid cells upregulate HDAC3 in a mouse model of retinal ischemia-reperfusion (IR) injury. However, whether this cellular event is an essential contributor to retinal IR injury is unknown",
      "strength": "medium"
    },
    {
      "pmid": "38378993",
      "year": "2024",
      "claim": "A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity.",
      "source": "Nat Neurosci",
      "abstract": "Disease, injury and aging induce pathological reactive astrocyte states that contribute to neurodegeneration. Modulating reactive astrocytes therefore represent an attractive therapeutic strategy. Here we describe the development of an astrocyte phenotypic screening platform for identifying chemical modulators of astrocyte reactivity. Leveraging this platform for chemical screening, we identify histone deacetylase 3 (HDAC3) inhibitors as effective suppressors of pathological astrocyte reactivity. We demonstrate that HDAC3 inhibition reduces molecular and functional characteristics of reactive astrocytes in vitro. Transcriptional and chromatin mapping studies show that HDAC3 inhibition disarms pathological astrocyte gene expression and function while promoting the expression of genes associated with beneficial astrocytes. Administration of RGFP966, a small molecule HDAC3 inhibitor, blocks reactive astrocyte formation and promotes neuroprotection in vivo in mice. Collectively, these resu",
      "strength": "medium"
    },
    {
      "pmid": "39824811",
      "year": "2025",
      "claim": "NKAPL facilitates transcription pause-release and bridges elongation to initiation during meiosis exit.",
      "source": "Nat Commun",
      "abstract": "Transcription elongation, especially RNA polymerase II (Pol II) pause-release, is less studied than transcription initiation in regulating gene expression during meiosis. It is also unclear how transcription elongation interplays with transcription initiation. Here, we show that depletion of NKAPL, a testis-specific protein distantly related to RNA splicing factors, causes male infertility in mice by blocking the meiotic exit and downregulating haploid genes. NKAPL binds to promoter-associated nascent transcripts and co-localizes with DNA-RNA hybrid R-loop structures at GAA-rich loci to enhance R-loop formation and facilitate Pol II pause-release. NKAPL depletion prolongs Pol II pauses and stalls the SOX30/HDAC3 transcription initiation complex on the chromatin. Genetic variants in NKAPL are associated with azoospermia in humans, while mice carrying an NKAPL frameshift mutation (M349fs) show defective meiotic exit and transcriptomic changes similar to NKAPL depletion. These findings id",
      "strength": "medium"
    },
    {
      "pmid": "28086213",
      "year": "2017",
      "claim": "Epigenetic regulation of general anesthesia-induced neonatal neurodegeneration.",
      "source": "Oncotarget",
      "strength": "medium"
    },
    {
      "pmid": "37466915",
      "year": "2023",
      "claim": "Ketogenic diet attenuates neuroinflammation and induces conversion of M1 microglia to M2 in an EAE model of multiple sclerosis by regulating the NF-κB/NLRP3 pathway and inhibiting HDAC3 and P2X7R activation.",
      "source": "Food Funct",
      "abstract": "Multiple sclerosis (MS) is an autoimmune disorder characterized by demyelination and neurodegeneration in the central nervous system (CNS); severe symptoms lead MS patients to use complementary treatments. Ketogenic diet (KD) shows wide neuroprotective effects, but the precise mechanisms underlying the therapeutic activity of KD in MS are unclear. The present study established a continuous 24 days experimental autoimmune encephalomyelitis (EAE) mouse model with or without KD. The changes in motor function, pathological hallmarks of EAE, the status of microglia, neuroinflammatory response and intracellular signaling pathways in mice were detected by the rotarod test, histological analysis, real-time PCR (RT-PCR) and western blotting. Our results showed that KD could prevent motor deficiency, reduce clinical scores, inhibit demyelination, improve pathological lesions and suppress microglial activation in the spinal cord of EAE mice. Meanwhile, KD shifted microglial polarization toward th",
      "strength": "medium"
    },
    {
      "pmid": "36046456",
      "year": "2022",
      "claim": "HDAC3 Inhibition Alleviates High-Glucose-Induced Retinal Ganglion Cell Death through Inhibiting Inflammasome Activation.",
      "source": "Biomed Res Int",
      "abstract": "PURPOSE: The exact effects of histone deacetylase 3 (HDAC3) inhibition in DR related retinal ganglion cells (RGCs) death remained unclear. This study is aimed at detecting the influence of HDAC3 on the high-glucose-induced retinal ganglion cell death. METHODS: The retinal HDAC3 expression in DR of different time points was analyzed by immunohistochemical assay and western blot. Besides, the expression of HDAC3 and both retinal thickness and RGC loss were analyzed. The effects of HDAC3 inhibitor on cell viability, oxidative stress, and apoptosis in high-glucose- (HG-) treated RGCs were analyzed. Both inflammatory and antioxidative factors were detected by ELISA. RESULTS: Advanced effects of HDAC3 inhibition on the expression of NLRP3 inflammasome were detected using western blots. High HDAC3 expression was detected only in the late DR mice (4 months of diabetes duration) but not early DR mice (2 months of diabetes duration). The immunohistochemical assay showed that HDAC3 expression was",
      "strength": "medium"
    },
    {
      "pmid": "21289184",
      "year": "2011",
      "claim": "Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta.",
      "source": "J Neurosci",
      "abstract": "Although it is well established that pharmacological inhibitors of classical histone deacetylases (HDACs) are protective in various in vivo models of neurodegenerative disease, the identity of the neurotoxic HDAC(s) that these inhibitors target to exert their protective effects has not been resolved. We find that HDAC3 is a protein with strong neurotoxic activity. Forced expression of HDAC3 induces death of otherwise healthy rat cerebellar granule neurons, whereas shRNA-mediated suppression of its expression protects against low-potassium-induced neuronal death. Forced expression of HDAC3 also promotes the death of rat cortical neurons and hippocampally derived HT22 cells, but has no effect on the viability of primary kidney fibroblasts or the HEK293 and HeLa cell lines. This suggests that the toxic effect of HDAC3 is cell selective and that neurons are sensitive to it. Neurotoxicity by HDAC3 is inhibited by treatment with IGF-1 as well as by the expression of a constitutively active f",
      "strength": "medium"
    },
    {
      "pmid": "35586419",
      "year": "2022",
      "claim": "Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.",
      "source": "ACS Med Chem Lett",
      "abstract": "Histone deacetylases (HDACs) 1-3 regulate chromatin structure and gene expression. These three enzymes are targets for cancer chemotherapy and have been studied for the treatment of immune disorders and neurodegeneration, but there is a lack of selective pharmacological tool compounds to unravel their individual roles. Potent inhibitors of HDACs 1-3 often display slow-binding kinetics, which causes a delay in inhibitor-enzyme equilibration and may affect assay readout. Here we compare the potencies and selectivities of slow-binding inhibitors measured by discontinuous and continuous assays. We find that entinostat, a clinical candidate, inhibits HDACs 1-3 by a two-step slow-binding mechanism with lower potencies than previously reported. In addition, we show that RGFP966, commercialized as an HDAC3-selective probe, is a slow-binding inhibitor with inhibitor constants of 57, 31, and 13 nM against HDACs 1-3, respectively. These data highlight the need for thorough kinetic investigation i",
      "strength": "medium"
    },
    {
      "pmid": "29211617",
      "year": "2018",
      "claim": "Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury.",
      "source": "J Ocul Pharmacol Ther",
      "abstract": "PURPOSE: HDAC3 regulates nuclear atrophy as an early response to axonal injury in retinal ganglion cells (RGCs) following optic nerve crush (ONC). Since conditional knockout of Hdac3 prevents nuclear atrophy post ONC, HDAC3 selective inhibition with RGFP966 through localized and systemic dosing of RGFP966 is necessary for application to acute and chronic models of optic nerve injury. METHODS: C57BL/6 mice were injected intravitreally with 1-10 μM RGFP966 immediately following ONC, and retinas were analyzed at 5, 7, and 14 days for metrics of nuclear atrophy and cell loss. Mice were similarly assessed after intraperitoneal (IP) injections with RGFP966 doses of 2-10 mg/kg, and eyes were harvested at 5, 14, and 28 days after ONC. H&E and BrdU staining were used to analyze toxicity to off-target tissues after 14 days of daily treatment with RGFP966. RESULTS: A single intravitreal injection of RGFP966 prevented histone deacetylation, heterochromatin formation, apoptosis, and DNA damage at 5",
      "strength": "medium"
    },
    {
      "pmid": "22918830",
      "year": "2012",
      "claim": "Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death.",
      "source": "J Biol Chem",
      "abstract": "Both neuroprotective and neurotoxic roles have previously been described for histone deacetylase-1 (HDAC1). Here we report that HDAC1 expression is elevated in vulnerable brain regions of two mouse models of neurodegeneration, the R6/2 model of Huntington disease and the Ca(2+)/calmodulin-dependent protein kinase (CaMK)/p25 double-transgenic model of tauopathic degeneration, suggesting a role in promoting neuronal death. Indeed, elevating HDAC1 expression by ectopic expression promotes the death of otherwise healthy cerebellar granule neurons and cortical neurons in culture. The neurotoxic effect of HDAC1 requires interaction and cooperation with HDAC3, which has previously been shown to selectively induce the death of neurons. HDAC1-HDAC3 interaction is greatly elevated under conditions of neurodegeneration both in vitro and in vivo. Furthermore, the knockdown of HDAC3 suppresses HDAC1-induced neurotoxicity, and the knockdown of HDAC1 suppresses HDAC3 neurotoxicity. As described previously for HDAC3, the neurotoxic effect of HDAC1 is inhibited by treatment with IGF-1, the expression of Akt, or the inhibition of glycogen synthase kinase 3β (GSK3β). In addition to HDAC3, HDAC1 has been shown to interact with histone deacetylase-related protein (HDRP), a truncated form of HDAC9, whose expression is down-regulated during neuronal death. In contrast to HDAC3, the interaction between HDRP and HDAC1 protects neurons from death, an effect involving acquisition of the deacetylase act",
      "strength": "medium"
    },
    {
      "pmid": "41912135",
      "year": "2026",
      "claim": "HOX Code-Based Stratification Reveals RUNX1T1-HDAC Reprogramming as a Targetable Driver of Lineage Plasticity Across Cancers.",
      "source": "Cancer Lett",
      "abstract": "Cancer remains a leading cause of death worldwide, with lineage plasticity emerging as a hallmark that drives therapy resistance and tumor progression by enabling cancer cells to alter identity and evade targeted therapies. Although genomic and transcriptomic aberrations correlate with lineage plasticity, the absence of scalable cross-cancer markers to rapidly identify plastic subtypes has limited predictive utility. Homeobox (HOX) genes encode transcription factors that define tissue identity through distinct expression patterns, or HOX codes, within specific lineages. By analyzing multi-omics data encompassing 39 HOX genes across more than 80,000 RNA-seq samples across 23 cancer types spanning 114 cancer subtypes, we found that HOX code expression robustly stratifies lineage-constrained and lineage-plastic states at a cross-cancer level. This framework revealed previously unrecognized lineage-plastic subtypes in prostate cancer, lung cancer, and acute myeloid leukemia (AML), each dis",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41888851",
      "year": "2026",
      "claim": "Microglial HDAC3 inhibits the migration of CD8-positive T cell in the development of EAE by restraining the expression of CCL5.",
      "source": "Cell Biosci",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41876476",
      "year": "2026",
      "claim": "EXPRESS: Identification of Acetylation-Related Molecular Signatures in Knee Osteoarthritis Patients with Significant Response to Warm-Needle Acupuncture Using Machine-Learning Approaches.",
      "source": "Mol Pain",
      "abstract": "OBJECTIVE: This study aims to delineate remodeling effects of acetylation-related gene expression in knee osteoarthritis (KOA) patients markedly responsive to warm-needle acupuncture (WNA) and identify key genes and immunoregulatory mechanisms. METHODS: A prospective self-paired design recruited 34 KOA patients to donate whole-blood samples before and after WNA treatment and further enroll them to perform transcriptome sequencing. Differential expression analysis identified acetylation-related genes followed by enrichment and protein-protein interaction analyses. Key genes were extracted via feature selection based on LASSO and SVM-RFE methods and further used to establish and validate a multigene logistic regression model. Consensus clustering was implemented to divide two acetylation subtypes (ACEcluster A/B) and further explore their immune characteristics by ssGSEA and immune-cell infiltration profiling. RESULTS: After treatment, samples exhibited global up-regulation of acetylatio",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41851071",
      "year": "2026",
      "claim": "Myeloid HDAC3 deletion protects against traumatic optic injury.",
      "source": "Cell Death Discov",
      "abstract": "Traumatic optic neuropathy (TON) occurs due to trauma to the optic nerve, resulting in blindness. Current management focuses primarily on supportive care, highlighting an urgent need to identify novel treatment targets. Neuronal expression of the enzyme histone deacetylase 3 (HDAC3) has been previously implicated in retinal ganglion cell (RGC) degeneration after optic nerve crush (ONC), a model of TON. Here we investigated the role of myeloid HDAC3 (i.e., HDAC3 expressed in microglia and macrophages) in RGC loss, axonal degeneration, and efferocytosis, a reparative process by which phagocytic myeloid cells engulf apoptotic cells. ONC injury was performed on myeloid-specific HDAC3 knockout (KO) and floxed control mice. Neurodegeneration and efferocytosis assays were assessed using retina flatmount immunolabeling and confocal imaging. RGC function was evaluated using pattern electroretinography (PERG). Axonal sprouting was quantified by anterograde transport of cholera toxin B injected intravitreally. Myelin debris clearance was assessed in optic nerves in vivo and in vitro using bone-marrow-derived macrophages isolated from myeloid HDAC3 KO and control mice. Myeloid HDAC3 deletion preserved RGC and improved axonal regeneration after ONC, together with improved retinal function assessed by PERG. Furthermore, the deletion of HDAC3 enhanced the phagocytic function of myeloid cells to effectively remove apoptotic cells and myelin debris, both in vivo and in vitro. These protective",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41844502",
      "year": "2026",
      "claim": "LncRNA SNHG5 promotes macrophage lipid accumulation and aggravates atherosclerosis by targeting the miR-216a-5p/HDAC3/ABCA1 axis.",
      "source": "Biochim Biophys Acta Mol Cell Biol Lipids",
      "abstract": "Long noncoding RNA small nucleolar RNA host gene 5 (SNHG5) has been implicated in cell death, glucose homeostasis, and tumor progression, yet its role in atherosclerosis (AS) remains unclear. In this study, SNHG5 expression was markedly elevated in aortic tissues of high-fat diet-fed apoE-/- mice and in ox-LDL-stimulated THP-1 macrophages. Lentiviral-mediated SNHG5 silencing in vivo reduced plaque burden, attenuated lipid deposition, increased collagen content, and decreased systemic inflammation. Moreover, SNHG5 knockdown increased plasma HDL-C and promoted reverse cholesterol transport. In mouse peritoneal macrophages and THP-1-derived foam cells, SNHG5 silencing enhanced cholesterol efflux to lipid-free apoA-I without affecting uptake, accompanied by upregulation of ABCA1. LXRα expression remained unchanged, whereas HDAC3 was downregulated; HDAC3 overexpression reversed the effects of SNHG5 knockdown on ABCA1 expression, cholesterol efflux, and foam cell formation. Subcellular fract",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41829110",
      "year": "2026",
      "claim": "The paper suggests GABA can suppress HDAC2/3 in astrocytes, which aligns with the hypothesis of targeted HDAC3 inhibition for neuroinflammation reduction.",
      "source": "Foods",
      "abstract": "As a widely available dietary supplement, γ-Aminobutyric acid (GABA) exhibits potential for early intervention against Alzheimer's disease (AD). This study demonstrates that GABA alleviates AD neuroinflammation, and its suppression of astrocytic pro-inflammatory cytokine expression through histone deacetylase (HDAC2/3) inhibition contributes to this effect. Here, in both the cerebral cortex of AD mice and Aβ-exposed U251 cells, pro-inflammatory cytokines and HDAC2/3 expression levels were elevat",
      "strength": "medium"
    },
    {
      "pmid": "41837847",
      "year": "2026",
      "claim": "Demonstrates GR/HDAC3's role in regulating cognitive signaling pathways, supporting the hypothesis's molecular mechanism.",
      "source": "FASEB J",
      "abstract": "Prenatal hypoxia (PH) is a common pregnancy complication that can lead to cognitive impairment in the offspring, but the underlying mechanisms remain unclear. In this study, we established a model of PH by exposing C57 mice to hypoxia (10.5% oxygen) environment from gestational day (GD) 12.5-17.5. We found that PH resulted in cognitive impairment and reduced hippocampal neurogenesis in male offspring compared to control offspring. Mechanistically, PH is a form of prenatal stress that promotes pl",
      "strength": "medium"
    },
    {
      "pmid": "41812251",
      "year": "2026",
      "claim": "Discovery of a HDAC3 degrader with anti-inflammatory activity provides additional evidence for targeted HDAC3 modulation.",
      "source": "J Med Chem",
      "abstract": "Histone deacetylase 3 (HDAC3) plays a pivotal role in inflammation by regulating transcriptional programs and promoting NLRP3 inflammasome activation. Here, we report the discovery of GS-1, a covalent HDAC3 degrader derived from a previously reported 18β-glycyrrhetinic acid derivative A18 via structural optimization. It selectively degraded HDAC3 in THP-1 cells, with minimal enzymatic HDAC inhibition and low cytotoxicity. LC-MS/MS analysis revealed covalent modification at Lys367, and molecular ",
      "strength": "medium"
    },
    {
      "pmid": "41736683",
      "year": "2026",
      "claim": "SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis.",
      "source": "Adv Sci (Weinh)"
    },
    {
      "pmid": "41023273",
      "year": "2026",
      "claim": "HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis.",
      "source": "Acta Pharmacol Sin"
    },
    {
      "pmid": "41535708",
      "year": "2026",
      "claim": "β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral edema in mice after ischemic stroke.",
      "source": "Acta Pharmacol Sin"
    },
    {
      "pmid": "41783166",
      "year": "2026",
      "claim": "Histone deacetylases: Function in tumor development and therapeutic prospects (Review).",
      "source": "Oncol Lett"
    },
    {
      "pmid": "41352543",
      "year": "2026",
      "claim": "Metabolomics identifies riboflavin as a therapeutic agent for acute pancreatitis.",
      "source": "J Nutr Biochem"
    },
    {
      "pmid": "41949720",
      "year": "2026",
      "claim": "Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis",
      "source": "Clin Rev Allergy Immunol",
      "strength": "moderate"
    },
    {
      "pmid": "41961925",
      "year": "2026",
      "claim": "Histone decrotonylation plays a distinct role in HIV latency",
      "source": "Sci Adv",
      "strength": "moderate"
    }
  ],
  "evidence_against": [
    {
      "pmid": "41160773",
      "year": "2025",
      "claim": "PROTAC-Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies",
      "source": "ChemMedChem",
      "abstract": "Proteolysis-targeting chimeras (PROTACs) have emerged as an excellent strategy for targeted protein degradation by the ubiquitin-proteasome system. Traditional inhibitors suppress the enzymatic activity, but the PROTACs utilize the method of total degradation of protein, promising prolonged and target-specific therapeutic efficacy. Histone deacetylases (HDACs) are epigenetic regulators, implicated in most cancers, neurodegeneration, and other inflammatory diseases. Therefore, HDAC-PROTAC development provides a unique approach to overcome the limitations of conventional HDAC inhibitors, including off-target effects, short duration of action, and resistance mechanisms. Recent advancements in HDAC-PROTACs lead to the design of selective degraders for specific isoforms of HDACs, including HDAC3, HDAC4, HDAC6, and HDAC8, representing superior efficacy in preclinical studies. This review highlights the progress of HDAC-targeting PROTACs, focusing on structural optimization, selectivity enhancements, and therapeutic applications with their degradation potential. However, various challenges include poor pharmacokinetics and bioavailability, and limited in vivo validation for further safety, efficacy analysis. Further research and optimization efforts will be pivotal in translating HDAC-PROTACs into clinically viable therapies for cancer and other epigenetic disorders.",
      "strength": "medium"
    },
    {
      "pmid": "41153431",
      "year": "2025",
      "claim": "Epigenetic Modulation and Neuroprotective Effects of Neurofabine-C in a Transgenic Model of Alzheimer's Disease",
      "source": "Genes (Basel)",
      "abstract": "Background: Currently, there are limited therapeutic or preventative strategies for neurodegenerative disorders due to the challenges in alleviating the progressive neuronal loss and neuroinflammation which are the primary characteristics of these diseases, ultimately leading to cell death and functional impairment. Cocoa-derived flavanols (Theobroma cacao) have been studied as potential bioactive compounds to modify and reverse various inflammation-associated diseases because of their remarkable antioxidant properties and capacity to modulate metabolic imbalance and reactive inflammatory responses. The faba bean (Vicia faba) extract obtained through nondenaturing biotechnological processes is a potent dopamine (DA) enhancer that has shown promising results as a neuroprotective agent against degeneration. Objective: This study will examine the synergistic effects of Neurofabine-C, a hybrid compound derived from cocoa and faba bean extracts, on various brain biomarkers in mice related to inflammatory, metabolic, and neurodegenerative processes. Methods: A triple-transgenic mouse model of neurodegeneration was treated with Neurofabine-C, and biomolecular data were obtained by performing biochemical and immunohistochemical analysis. Results: Neurofabine-C prevented neuronal degeneration (NeuN), mitigated the neuro-inflammatory processes triggered (decreased expression of reactive astrocytes (GFAP)), and induced an increase in neurogenesis in the treated cortical mice brain (PAX6",
      "strength": "medium"
    },
    {
      "pmid": "40667573",
      "year": "2025",
      "claim": "Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment",
      "source": "Future Med Chem",
      "abstract": "Epigenetic therapy and targeted protein degradation have converged in the development of histone deacetylases (HDACs)-targeting proteolysis-targeting chimeras (PROTACs), offering a novel approach to cancer treatment. Unlike traditional HDAC inhibitors, HDAC-PROTACs facilitate selective degradation of HDACs via the ubiquitin-proteasome system, effectively eliminating both enzymatic and scaffolding functions. These bifunctional molecules recruit HDACs to E3 ligases, triggering ubiquitination and subsequent proteasomal degradation. PROTACs demonstrate catalytic activity, requiring lower dosages while sustaining prolonged effects compared to inhibitors. Advances in PROTAC chemistry have led to the development of selective degraders targeting distinct HDAC classes. Class I HDAC-targeting PROTACs, such as PROTAC 1 and PROTAC 2, induce robust degradation of HDAC1-3 with nanomolar DC50 values, showing promising anti-cancer activity. Similarly, class IIa and IIb HDAC PROTACs, including selective HDAC4 and HDAC6 degraders, exhibit potent anti-proliferative effects in leukemia, lymphoma, and multiple myeloma models. Despite these advancements, challenges persist in optimizing selectivity, linker design, and bioavailability while mitigating off-target effects. Future strategies include enhancing tumor-specific delivery, refining ligand-E3 ligase compatibility, and integrating combination therapies to overcome resistance. This review explores the mechanistic insights, therapeutic potentia",
      "strength": "medium"
    },
    {
      "pmid": "34151764",
      "year": "2022",
      "claim": "Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective.",
      "source": "Curr Neuropharmacol",
      "abstract": "Neurodegenerative diseases are a group of pathological conditions that cause motor incordination (jerking movements), cognitive and memory impairments result from degeneration of neurons in a specific area of the brain. Oxidative stress, mitochondrial dysfunction, excitotoxicity, neuroinflammation, neurochemical imbalance and histone deacetylase enzymes (HDAC) are known to play a crucial role in neurodegeneration. HDAC is classified into four categories (class I, II, III and class IV) depending upon their location and functions. HDAC1 and 2 are involved in neurodegeneration, while HDAC3-11 and class III HDACs are beneficial as neuroprotective. HDACs are localized in different parts of the brain- HDAC1 (hippocampus and cortex), HDAC2 (nucleus), HDAC3, 4, 5, 7 and 9 (nucleus and cytoplasm), HDAC6 & HDAC7 (cytoplasm) and HDAC11 (Nucleus, cornus ammonis 1 and spinal cord). In pathological conditions, HDAC up-regulates glutamate, phosphorylation of tau, and glial fibrillary acidic proteins while down-regulating BDNF, Heat shock protein 70 and Gelsolin. Class III HDACs are divided into seven sub-classes (SIRT1-SIRT7). Sirtuins are localized in the different parts of the brain and neuron -Sirt1 (nucleus), Sirt2 (cortex, striatum, hippocampus and spinal cord), Sirt3 (mitochondria and cytoplasm), Sirt4, Sirt5 & Sirt6 (mitochondria), Sirt7 (nucleus) and Sirt8 (nucleolus). SIRTs (1, 3, 4, and 6) are involved in neuronal survival, proliferation and modulating stress response, and SIRT2 i",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "39513228",
      "year": "2024",
      "claim": "The Two Faces of HDAC3: Neuroinflammation in Disease and Neuroprotection in Recovery.",
      "source": "Epigenomics",
      "abstract": "Histone deacetylase 3 (HDAC3) is a critical regulator of gene expression, influencing a variety of cellular processes in the central nervous system. As such, dysfunction of this enzyme may serve as a key driver in the pathophysiology of various neuropsychiatric disorders and neurodegenerative diseases. HDAC3 plays a crucial role in regulating neuroinflammation, and is now widely recognized as a major contributor to neurological conditions, as well as in promoting neuroprotective recovery following brain injury, hemorrhage and stroke. Emerging evidence suggests that pharmacological inhibition of HDAC3 can mitigate behavioral and neuroimmune deficits in various brain diseases and disorders, offering a promising therapeutic strategy. Understanding HDAC3 in the healthy brain lays the necessary foundation to define and resolve its dysfunction in a disease state. This review explores the mechanisms of HDAC3 in various cell types and its involvement in disease pathology, emphasizing the potential of HDAC3 inhibition to address neuroimmune, gene expression and behavioral deficits in a range of neurodegenerative and neuropsychiatric conditions. Histone deacetylase 3 (HDAC3) is an essential enzyme that helps regulate gene expression in the brain, influencing a variety of processes critical for brain health. Dysfunction of this enzyme may contribute to various brain disorders and diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, spinal cord injury, stro",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "38711064",
      "year": "2024",
      "claim": "Deficiency of histone deacetylases 3 in macrophage alleviates monosodium urate crystals-induced gouty inflammation in mice",
      "source": "Arthritis Res Ther",
      "abstract": "BACKGROUND: Gout is caused by monosodium urate (MSU) crystals deposition to trigger immune response. A recent study suggested that inhibition of Class I Histone deacetylases (HDACs) can significantly reduce MSU crystals-induced inflammation. However, which one of HDACs members in response to MSU crystals was still unknown. Here, we investigated the roles of HDAC3 in MSU crystals-induced gouty inflammation. METHODS: Macrophage specific HDAC3 knockout (KO) mice were used to investigate inflammatory profiles of gout in mouse models in vivo, including ankle arthritis, foot pad arthritis and subcutaneous air pouch model. In the in vitro experiments, bone marrow-derived macrophages (BMDMs) from mice were treated with MSU crystals to assess cytokines, potential target gene and protein. RESULTS: Deficiency of HDAC3 in macrophage not only reduced MSU-induced foot pad and ankle joint swelling but also decreased neutrophils trafficking and IL-1β release in air pouch models. In addition, the levels of inflammatory genes related to TLR2/4/NF-κB/IL-6/STAT3 signaling pathway were significantly decreased in BMDMs from HDAC3 KO mice after MSU treatment. Moreover, RGFP966, selective inhibitor of HDAC3, inhibited IL-6 and TNF-α production in BMDMs treated with MSU crystals. Besides, HDAC3 deficiency shifted gene expression from pro-inflammatory macrophage (M1) to anti-inflammatory macrophage (M2) in BMDMs after MSU challenge. CONCLUSIONS: Deficiency of HDAC3 in macrophage alleviates MSU crystal",
      "strength": "medium"
    },
    {
      "pmid": "40485011",
      "year": "2025",
      "claim": "Targeting HDAC3 Suppresses Ferroptosis and Demyelination in White Matter Injury by Restoring PDK4-Mediated Iron Homeostasis",
      "source": "CNS Neurosci Ther",
      "abstract": "AIM: White matter injury (WMI), characterized by white matter degeneration and iron deposition, contributes to neurological dysfunction. Histone deacetylase 3 (HDAC3) is implicated in neurodegenerative processes, yet its role in WMI-associated ferroptosis remains unclear. METHODS: Clinical assessments in WMI patients revealed correlations between serum iron, α-synuclein, and antioxidant levels and MRI-confirmed white matter degeneration. In a cuprizone-induced demyelination mouse model, white matter integrity, oligodendrocyte dysfunction, iron accumulation, and lipid peroxidation were evaluated through behavioral testing, histological staining, and biochemical analyses. To identify potential molecular targets of HDAC3-mediated ferroptosis, CUT&Tag sequencing was performed. The involvement of this pathway was further validated in vitro using iron overload assays and in vivo through HDAC3 overexpression via AAV vectors. RESULTS: In the present study, HDAC3 expression was elevated following demyelination and was suppressed by RGFP966 treatment. Brain MRI findings from clinical patients and histological analyses in CPZ-treated mice revealed disrupted iron metabolism following white matter injury, likely driven by increased iron deposition and lipid peroxidation in the affected regions. HDAC3 inhibition alleviated oligodendrocyte lineage dysfunction, preserved myelin integrity, and mitigated cognitive and motor deficits induced by demyelination. CUT&Tag sequencing suggested that t",
      "strength": "medium"
    },
    {
      "pmid": "23913134",
      "year": "2014",
      "claim": "Histone deacetylase 3 as a novel therapeutic target in multiple myeloma",
      "source": "Leukemia",
      "abstract": "Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable antitumor activities in the preclinical setting; however, their clinical utility is limited because of unfavorable toxicities associated with their broad range HDAC inhibitory effects. Isoform-selective HDAC inhibition may allow for MM cytotoxicity without attendant side effects. In this study, we demonstrated that HDAC3 knockdown and a small-molecule HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3). Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth. Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3. Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity. Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM. Our results indicate that HDAC3 represents a promising therapeutic target, and validate",
      "strength": "medium"
    }
  ],
  "market_price": 0.9787
}